Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hong Thai is active.

Publication


Featured researches published by Hong Thai.


PLOS ONE | 2010

Epidemic History and Evolutionary Dynamics of Hepatitis B Virus Infection in Two Remote Communities in Rural Nigeria

Joseph C. Forbi; Gilberto Vaughan; Michael A. Purdy; David S. Campo; Guoliang Xia; Lilia Ganova-Raeva; Hong Thai; Yury Khudyakov

Background In Nigeria, hepatitis B virus (HBV) infection has reached hyperendemic levels and its nature and origin have been described as a puzzle. In this study, we investigated the molecular epidemiology and epidemic history of HBV infection in two semi-isolated rural communities in North/Central Nigeria. It was expected that only a few, if any, HBV strains could have been introduced and effectively transmitted among these residents, reflecting limited contacts of these communities with the general population in the country. Methods and Findings Despite remoteness and isolation, ∼11% of the entire population in these communities was HBV-DNA seropositive. Analyses of the S-gene sequences obtained from 55 HBV-seropositive individuals showed the circulation of 37 distinct HBV variants. These HBV isolates belong predominantly to genotype E (HBV/E) (n = 53, 96.4%), with only 2 classified as sub-genotype A3 (HBV/A3). Phylogenetic analysis showed extensive intermixing between HBV/E variants identified in these communities and different countries in Africa. Quasispecies analysis of 22 HBV/E strains using end-point limiting-dilution real-time PCR, sequencing and median joining networks showed extensive intra-host heterogeneity and inter-host variant sharing. To investigate events that resulted in such remarkable HBV/E diversity, HBV full-size genome sequences were obtained from 47 HBV/E infected persons and P gene was subjected to Bayesian coalescent analysis. The time to the most recent common ancestor (tMRCA) for these HBV/E variants was estimated to be year 1952 (95% highest posterior density (95% HPD): 1927–1970). Using additional HBV/E sequences from other African countries, the tMRCA was estimated to be year 1948 (95% HPD: 1924–1966), indicating that HBV/E in these remote communities has a similar time of origin with multiple HBV/E variants broadly circulating in West/Central Africa. Phylogenetic analysis and statistical neutrality tests suggested rapid HBV/E population expansion. Additionally, skyline plot analysis showed an increase in the size of the HBV/E-infected population over the last ∼30–40 years. Conclusions Our data suggest a massive introduction and relatively recent HBV/E expansion in the human population in Africa. Collectively, these data show a significant shift in the HBV/E epidemic dynamics in Africa over the last century.


Nature Communications | 2012

Convergence and coevolution of Hepatitis B virus drug resistance

Hong Thai; David S. Campo; James Lara; Zoya Dimitrova; Guoliang Xia; Lilia Ganova-Raeva; Chong Gee Teo; Anna Lok; Yury Khudyakov

Treatment with lamivudine of patients infected with hepatitis B virus (HBV) results in a high rate of drug resistance, which is primarily associated with the rtM204I/V substitution in the HBV reverse transcriptase domain. Here we show that the rtM204I/V substitution, although essential, is insufficient for establishing resistance against lamivudine. The analysis of 639 HBV whole-genome sequences obtained from 11 patients shows that rtM204I/V is independently acquired by more than one intra-host HBV variant, indicating the convergent nature of lamivudine resistance. The differential capacity of HBV variants to develop drug resistance suggests that fitness effects of drug-resistance mutations depend on the genetic structure of the HBV genome. An analysis of Bayesian networks that connect rtM204I/V to many sites of HBV proteins confirms that lamivudine resistance is a complex trait encoded by the entire HBV genome rather than by a single mutation. These findings have implications for public health and offer a more general framework for understanding drug resistance.


The Journal of Infectious Diseases | 2016

Accurate Genetic Detection of Hepatitis C Virus Transmissions in Outbreak Settings

David S. Campo; Guoliang Xia; Zoya Dimitrova; Yulin Lin; Joseph C. Forbi; Lilia Ganova-Raeva; Lili Punkova; Hong Thai; Pavel Skums; Seth Sims; Inna Rytsareva; Gilberto Vaughan; Ha-Jung Roh; Michael A. Purdy; Amanda Sue; Yury Khudyakov

Hepatitis C is a major public health problem in the United States and worldwide. Outbreaks of hepatitis C virus (HCV) infections are associated with unsafe injection practices, drug diversion, and other exposures to blood and are difficult to detect and investigate. Here, we developed and validated a simple approach for molecular detection of HCV transmissions in outbreak settings. We obtained sequences from the HCV hypervariable region 1 (HVR1), using end-point limiting-dilution (EPLD) technique, from 127 cases involved in 32 epidemiologically defined HCV outbreaks and 193 individuals with unrelated HCV strains. We compared several types of genetic distances and calculated a threshold, using minimal Hamming distances, that identifies transmission clusters in all tested outbreaks with 100% accuracy. The approach was also validated on sequences obtained using next-generation sequencing from HCV strains recovered from 239 individuals, and findings showed the same accuracy as that for EPLD. On average, the nucleotide diversity of the intrahost population was 6.2 times greater in the source case than in any incident case, allowing the correct detection of transmission direction in 8 outbreaks for which source cases were known. A simple and accurate distance-based approach developed here for detecting HCV transmissions streamlines molecular investigation of outbreaks, thus improving the public health capacity for rapid and effective control of hepatitis C.


Journal of Hepatology | 2014

Hepatitis B virus infection among HIV-infected pregnant women in Malawi and transmission to infants

Charles Chasela; Athena P. Kourtis; Patrick G. Wall; Jan Drobeniuc; Caroline C. King; Hong Thai; Eyasu H. Teshale; Mina C. Hosseinipour; Sascha R. Ellington; Mary B. Codd; Denise J. Jamieson; Rod Knight; Patricia Fitzpatrick; Saleem Kamili; Irving Hoffman; Noel Mumba; Deborah Kamwendo; Francis Martinson; William G. Powderly; Chong Gee Teo; Charles van der Horst

BACKGROUND & AIMS The extent of HBV infection to infants of HBV/HIV-coinfected pregnant women in sub-Saharan Africa is unknown. The aim of this study was to assess prevalence of HBV infection among antiretroviral-naïve, HIV-infected pregnant women in Malawi and examine HBV transmission to their infants. METHODS Plasma from 2048 HIV-infected, Malawian women and their infants were tested for markers of HBV infection. Study participants were provided standard-of-care health services, which included administration of pentavalent vaccine to infants at 6, 10, and 14 weeks of age. RESULTS One-hundred and three women (5%) were HBsAg-positive; 70 of these HBsAg-positive women were also HBV-DNA-positive. Sixteen women (0.8%) were HBV-DNA-positive but HBsAg-negative. Five of 51 infants (9.8%) born to HBsAg-positive and/or HBV-DNA-positive women were HBV-DNA-positive by 48 weeks of age.HBV DNA concentrations of two infants of mothers who received extended lamivudine-containing anti-HIV prophylaxis were <4 log10 IU/ml compared to ⩾ 8 log10 IU/ml in three infants of mothers who did not. CONCLUSIONS HBV DNA was detected in nearly 10% of infants born to HBV/HIV-coinfected women. Antenatal testing for HIV and HBV, if instituted, can facilitate implementation of prophylactic measures against infant infection by both viruses.


PLOS ONE | 2011

Evaluation of intra-host variants of the entire hepatitis B virus genome.

Xiangjun Zhai; Hong Thai; Davis S. Campo; Guoliang Xia; Lilia Ganova-Raeva; Jan Drobeniuc; Yury Khudyakov

Genetic analysis of hepatitis B virus (HBV) frequently involves study of intra-host variants, identification of which is commonly achieved using short regions of the HBV genome. However, the use of short sequences significantly limits evaluation of genetic relatedness among HBV strains. Although analysis of HBV complete genomes using genetic cloning has been developed, its application is highly labor intensive and practiced only infrequently. We describe here a novel approach to whole genome (WG) HBV quasispecies analysis based on end-point, limiting-dilution real-time PCR (EPLD-PCR) for amplification of single HBV genome variants, and their subsequent sequencing. EPLD-PCR was used to analyze WG quasispecies from serum samples of patients (n = 38) infected with HBV genotypes A, B, C, D, E and G. Phylogenetic analysis of the EPLD-isolated HBV-WG quasispecies showed the presence of mixed genotypes, recombinant variants and sub-populations of the virus. A critical observation was that HBV-WG consensus sequences obtained by direct sequencing of PCR fragments without EPLD are genetically close, but not always identical to the major HBV variants in the intra-host population, thus indicating that consensus sequences should be judiciously used in genetic analysis. Sequence-based studies of HBV WG quasispecies should afford a more accurate assessment of HBV evolution in various clinical and epidemiological settings.


American Journal of Infection Control | 2014

Hepatitis B outbreak associated with a home health care agency serving multiple assisted living facilities in Texas, 2008-2010

Yenlik Zheteyeva; Pritish K. Tosh; Priti R. Patel; Diana Martinez; Cindy Kilborn; Debo Awosika-Olumo; Salma Khuwaja; Syed Ibrahim; Anthony Ryder; Rania A. Tohme; Yury Khudyakov; Hong Thai; Jan Drobeniuc; Gary Heseltine; Alice Guh

We investigated a multifacility outbreak of acute hepatitis B virus infection involving 21 residents across 10 assisted living facilities in Texas during the period January 2008 through July 2010. Epidemiologic and laboratory data suggested that these infections belonged to a single outbreak. The only common exposure was receipt of assisted monitoring of blood glucose from the same home health care agency. Improved infection control oversight and training of assisted living facility and home health care agency personnel providing assisted monitoring of blood glucose is needed.


Journal of the International Association of Providers of AIDS Care | 2013

An evaluation of hepatitis B virus diagnostic methods and responses to antiretroviral therapy among HIV-infected women in Thailand.

Philip J. Peters; Janet M. McNicholl; Boonyos Raengsakulrach; Punneeporn Wasinrapee; Famui Mueanpai; Winai Ratanasuwan; Poj Intalapaporn; Jan Drobeniuc; Hong Thai; Guoliang Xia; Saleem Kamili; Yury Khudyakov; Paul J. Weidle; Chong Gee Teo; Michelle S. McConnell

Coinfection with HIV and hepatitis B virus (HBV) is common in resource-limited settings but is frequently not diagnosed. The authors retrospectively tested specimens for HBV in HIV-infected Thai women who had participated in an antiretroviral therapy (ART) clinical study. A substantial proportion (27 of 211; 13%) of HIV-infected women were HBV coinfected. Among HIV/HBV-coinfected women, the authors observed similar rates of antiretroviral-associated liver toxicity (despite nevirapine [NVP] use) and CD4 count reconstitution as observed in HIV-monoinfected women. Hepatitis B surface antigen (HBsAg) screening detected the majority (81%) of HBV coinfections, including all 5 HBV-coinfected women who did not suppress HBV despite 48 weeks of lamivudine (3TC)-containing ART and could be used to tailor ART for patients diagnosed with HBV coinfection in accordance with World Health Organization guidelines. Although HBsAg screening did not diagnose 5 occult HBV coinfections, these women achieved HBV suppression on 3TC-containing ART, suggesting that not detecting occult HBV coinfection would have limited clinical impact.


in Silico Biology | 2011

Coordinated evolution of the Hepatitis B Virus Polymerase

David S. Campo; Zoya Dimitrova; James Lara; Mike Purdy; Hong Thai; Lilia Ganova-Raeva; X. Zhai; Joseph C. Forbi; Chong-Gee Teo; Yuri Khudyakov

The detection of compensatory mutations that abrogate negative fitness effects of drug-resistance and vaccine-escape mutations indicates the important role of epistatic connectivity in evolution of viruses, especially under the strong selection pressures. Mapping of epistatic connectivity in the form of coordinated substitutions should help to characterize molecular mechanisms shaping viral evolution and provides a tool for the development of novel anti-viral drugs and vaccines. We analyzed coordinated variation among amino acid sites in 370 the hepatitis B virus (HBV) polymerase sequences using Bayesian networks. Among the HBV polymerase domains the spacer domain separating terminal protein from the reverse-transcriptase domain, showed the highest network centrality. Coordinated substitutions preserve the hydrophobicity and charge of Spacer. Maximum likelihood estimates of codon selection showed that Spacer contains the highest number of positively selected sites. Identification of 67% of the domain lacking an ordered structure suggests that Spacer belongs to the class of intrinsically disordered domains and proteins whose crucial functional role in the regulation of transcription, translation and cellular signal transduction has only recently been recognized. Spacer plays a central role in the epistatic network associating substitutions across the HBV genome, including those conferring viral virulence, drug resistance and vaccine escape. The data suggest that Spacer is extensively involved in coordination of HBV evolution.


American Journal of Kidney Diseases | 2016

Hepatitis B Reverse Seroconversion and Transmission in a Hemodialysis Center: A Public Health Investigation and Case Report.

Sarah Rhea; Anne C. Moorman; Robert Pace; Victoria Mobley; Jennifer MacFarquhar; Edward Robinson; Tonya Hayden; Hong Thai; Jan Drobeniuc; John T. Brooks; Zack Moore; Priti R. Patel

In March 2013, public health authorities were notified of a new hepatitis B virus (HBV) infection in a patient receiving hemodialysis. We investigated to identify the source and prevent additional infections. We reviewed medical records, interviewed the index patient regarding hepatitis B risk factors, performed HBV molecular analysis, and observed infection control practices at the outpatient hemodialysis facility where she received care. The index patients only identified hepatitis B risk factor was hemodialysis treatment. The facility had no other patients with known active HBV infection. One patient had evidence of a resolved HBV infection. Investigation of this individual, who was identified as the source patient, indicated that HBV reverse seroconversion and reactivation had occurred in the setting of HIV (human immunodeficiency virus) infection and a failed kidney transplant. HBV whole genome sequences analysis from the index and source patients indicated 99.9% genetic homology. Facility observations revealed multiple infection control breaches. Inadequate dilution of the source patients sample during HBV testing might have led to a false-negative result, delaying initiation of hemodialysis in isolation. In conclusion, HBV transmission occurred after an HIV-positive hemodialysis patient with transplant-related immunosuppression experienced HBV reverse seroconversion and reactivation. Providers should be aware of this possibility, especially among severely immunosuppressed patients, and maintain stringent infection control.


Clinical Infectious Diseases | 2018

Large Outbreak of Hepatitis C Virus Associated With Drug Diversion by a Healthcare Technician

Sharon Alroy-Preis; Elizabeth R. Daly; Christine Adamski; Jodie Dionne-Odom; Elizabeth A. Talbot; Fengxiang Gao; Steffany J. Cavallo; Katrina Hansen; Jennifer Mahoney; Erin Metcalf; Carol Loring; Christine Bean; Jan Drobeniuc; Guoliang Xia; Saleem Kamili; Jose T. Montero; Sarah Krycki; Karin Salome; Darlene Morse; Abigail Mathewson; Patricia Jackson; Maureen MacDonald; Jill Drouin; Pamela Hill; Marylee Greaves; Heather Barto; Ken Dufault; Kim Budde; John J Dreisig; Benjamin Chan

Background In May 2012, the New Hampshire (NH) Division of Public Health Services (DPHS) was notified of 4 persons with newly diagnosed hepatitis C virus (HCV) infection at hospital X. Initial investigation suggested a common link to the hospital cardiac catheterization laboratory (CCL) because the infected persons included 3 CCL patients and a CCL technician. NH DPHS initiated an investigation to determine the source and control the outbreak. Methods NH DPHS conducted site visits, case patient and employee interviews, medical record and medication use review, and employee and patient HCV testing using enzyme immunoassay for anti-HCV, reverse-transcription polymerase chain reaction for HCV RNA, nonstructural 5B (NS5B) and hypervariable region 1 (HVR1) sequencing, and quasispecies analysis. Results HCV HVR1 analysis of the first 4 cases confirmed a common source of infection. HCV testing identified 32 of 1074 CCL patients infected with the outbreak strain, including 3 patients coinfected with >1 HCV strain. The epidemiologic investigation revealed evidence of drug diversion by the HCV-infected technician, evidenced by gaps in controlled medication control, higher fentanyl use during procedures for confirmed cases, and building card key access records documenting the presence of the technician during days when transmission occurred. The employees status as a traveling technician led to a multistate investigation, which identified additional cases at prior employment sites. Conclusions This is the largest laboratory-confirmed drug diversion-associated HCV outbreak published to date. Recommendations to reduce drug diversion risk and to conduct outbreak investigations are provided.

Collaboration


Dive into the Hong Thai's collaboration.

Top Co-Authors

Avatar

Lilia Ganova-Raeva

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Yury Khudyakov

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Guoliang Xia

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

David S. Campo

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

James Lara

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Jan Drobeniuc

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Joseph C. Forbi

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Zoya Dimitrova

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Saleem Kamili

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Yulin Lin

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge